Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Beam Therapeutics Inc BEAM

Healthcare Biotechnology
Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead... see more

Recent & Breaking News (NDAQ:BEAM)

Beam Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire 9 days ago

Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual Meeting

GlobeNewswire December 8, 2024

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting

GlobeNewswire December 7, 2024

Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer

GlobeNewswire December 6, 2024

Beam Therapeutics Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma Strategy and Commercial Leader

GlobeNewswire December 4, 2024

Beam Therapeutics to Participate in 2024 Jefferies London Healthcare Conference

GlobeNewswire November 12, 2024

Beam Therapeutics to Present Data Across Hematology Franchise, Including First Clinical Data for BEAM-101 in Sickle Cell Disease and ESCAPE Non-human Primate Data, at American Society of Hematology (ASH) Annual Meeting

GlobeNewswire November 5, 2024

Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority Programs

GlobeNewswire November 5, 2024

Beam Therapeutics to Hold Conference Call to Discuss Third Quarter 2024 Financial Results and Abstracts Accepted for Presentation at ASH Annual Meeting

GlobeNewswire October 29, 2024

Beam Therapeutics Reports Pipeline Updates and Second Quarter 2024 Financial Results

GlobeNewswire August 6, 2024

Beam Therapeutics Announces Transition of Chief Financial Officer

GlobeNewswire July 15, 2024

Beam Therapeutics Announces First Patient Dosed in the Phase 1/2 Study of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD)

GlobeNewswire June 26, 2024

Beam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell Disease

GlobeNewswire June 14, 2024

Beam Therapeutics to Participate in Jefferies Global Healthcare Conference

GlobeNewswire May 30, 2024

Beam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 at 2024 European Hematology Association (EHA) Hybrid Congress

GlobeNewswire May 14, 2024

Beam Therapeutics to Participate in RBC Capital Markets 2024 Global Healthcare Conference

GlobeNewswire May 8, 2024

Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results

GlobeNewswire May 7, 2024

Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

GlobeNewswire March 26, 2024

Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences

GlobeNewswire February 28, 2024

Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones

GlobeNewswire February 27, 2024